Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.

@article{Kruis2001LowDB,
  title={Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.},
  author={Wolfgang Kruis and Stefan Schreiber and Dorothea Theuer and James Brandes and Ekkehard Sch{\"u}tz and S Howaldt and Bernd Krakamp and J Haemling and Huberthus M{\"o}nnikes and Irmtraut Koop and Manfred Stolte and D Pallant and Uwe W Ewald},
  journal={Gut},
  year={2001},
  volume={49 6},
  pages={783-9}
}
BACKGROUND Balsalazide is a new 5-aminosalicylic acid (5-ASA) containing prodrug. Its efficacy in comparison with standard mesalazine therapy and the optimum dose for maintaining remission of ulcerative colitis are still unclear. AIMS To compare the relapse preventing effect and safety profile of two doses of balsalazide and a standard dose of Eudragit coated mesalazine. METHODS A total of 133 patients with ulcerative colitis in remission were recruited to participate in a double blind… CONTINUE READING
31 Citations
19 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 19 references

Randomized comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis

  • MG Courtney, DP Numnes, CF Bergin
  • Lancet
  • 1992

Similar Papers

Loading similar papers…